[go: up one dir, main page]

ATE235914T1 - Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen - Google Patents

Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Info

Publication number
ATE235914T1
ATE235914T1 AT96923511T AT96923511T ATE235914T1 AT E235914 T1 ATE235914 T1 AT E235914T1 AT 96923511 T AT96923511 T AT 96923511T AT 96923511 T AT96923511 T AT 96923511T AT E235914 T1 ATE235914 T1 AT E235914T1
Authority
AT
Austria
Prior art keywords
progression
inhibiting
neuropathic pain
achieveing
analgesia
Prior art date
Application number
AT96923511T
Other languages
English (en)
Inventor
Gary Arthur Amstutz
Stephen Scott Bowersox
Kishorchandra Gohil
Peter Isadore Adriaenssens
Ramasharma Kristipati
Theresa Gadbois
Mark Raymond Pettus
Robert R Luther
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE235914T1 publication Critical patent/ATE235914T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT96923511T 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen ATE235914T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia
PCT/US1996/011041 WO1997001351A1 (en) 1995-06-27 1996-06-26 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Publications (1)

Publication Number Publication Date
ATE235914T1 true ATE235914T1 (de) 2003-04-15

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96923511T ATE235914T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03007342T ATE359086T1 (de) 1995-06-27 1996-06-26 Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen

Country Status (13)

Country Link
EP (2) EP1336409B1 (de)
JP (1) JP2838073B2 (de)
AT (2) ATE235914T1 (de)
AU (1) AU695166B2 (de)
CA (1) CA2224795C (de)
DE (3) DE122005000043I2 (de)
DK (2) DK1336409T3 (de)
ES (2) ES2194998T3 (de)
FR (1) FR05C0027I2 (de)
LU (1) LU91181I2 (de)
NL (1) NL300201I2 (de)
PT (2) PT835126E (de)
WO (1) WO1997001351A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP1054896A1 (de) * 1998-02-20 2000-11-29 Zeneca Limited Analgetische peptide von grammostola spatulata gift und deren verwendung
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2386566A3 (de) 2002-12-02 2012-02-15 Xenome Ltd Chi-Conotoxin-Peptide (II)
JP4565087B2 (ja) 2002-12-02 2010-10-20 ゼノム リミティッド 新規なχ−コノトキシン・ペプチド（−Ｉ）
CN100589839C (zh) 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2930900C (en) 2003-10-02 2018-10-16 Jazz Pharmaceuticals International Limited Combinations of ziconotide and opioids for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
EP2077854B1 (de) * 2006-11-04 2013-01-23 Anygen Co., Ltd. Omega-conotoxine
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2300044A4 (de) * 2008-05-06 2012-04-18 Relevare Aust Pty Ltd Verfahren und zusammensetzungen zur behandlung von schmerzen mit omega-conotoxinen
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX345283B (es) 2008-12-31 2017-01-24 Ardelyx Inc Compuestos y metodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrogeno (nhe) en el tratamiento de trastornos asociados con retencion de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
KR20230132619A (ko) 2013-04-12 2023-09-15 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
EP1336409B1 (de) 2007-04-11
FR05C0027I1 (de) 2005-08-12
PT1336409E (pt) 2007-06-29
EP0835126B1 (de) 2003-04-02
DK0835126T3 (da) 2003-07-14
JP2838073B2 (ja) 1998-12-16
JPH09104634A (ja) 1997-04-22
EP1336409A1 (de) 2003-08-20
WO1997001351A1 (en) 1997-01-16
DE122005000043I2 (de) 2006-08-03
ES2194998T3 (es) 2003-12-01
NL300201I2 (nl) 2006-02-01
AU695166B2 (en) 1998-08-06
DE69627153T2 (de) 2003-12-04
LU91181I2 (fr) 2005-09-06
DE69627153D1 (de) 2003-05-08
HK1058146A1 (en) 2004-05-07
ES2283671T3 (es) 2007-11-01
AU6400296A (en) 1997-01-30
ATE359086T1 (de) 2007-05-15
DE122005000043I1 (de) 2006-06-29
DE69637021D1 (de) 2007-05-24
EP0835126A1 (de) 1998-04-15
DE69637021T2 (de) 2008-01-10
DK1336409T3 (da) 2007-08-13
NL300201I1 (nl) 2005-09-01
CA2224795A1 (en) 1997-01-16
FR05C0027I2 (de) 2006-12-29
CA2224795C (en) 2001-04-03
PT835126E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
ATE359086T1 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
ZA975323B (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis.
MY131458A (en) Pyrolopyrimidine compounds
MX9709915A (es) Heterociclos de peptidilo y composiciones que los contienen, utiles en el tratamiento de trastornos relacionados con trombina, y uso de los mismos.
DE69117117D1 (de) Reinigungszusammensetzung zur Vorbeugung und Milderung von Hautreizungen
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE330554T1 (de) Enossales einzelzahnimplantat
DE69309763D1 (de) Vorrichtung zur Herstellung von Rohren
EP0735870A4 (de) Verwendung von phospholipase-a2-inhibitoren zur behandlung der alzheimer-krankheit
DE69429023D1 (de) Vorrichtung zur Herstellung von Stempeln
DE59309089D1 (de) Lichtempfindliches Gemisch zur Herstellung von Relief- und Druckformen
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DK0743060T3 (da) Anvendelse af tandplejemidler indeholdende bovint colostrum
DE59600130D1 (de) Vorrichtung zur Versorgung von Knochenbrüchen
DE59408857D1 (de) Vorrichtung zur kontinuierlichen Herstellung von Polyacetalen und ihre Verwendung
DE69316498D1 (de) Vorrichtung zur Herstellung von Schablonen
GR3029489T3 (en) Use of leflunomid for the inhibition of interleukin 8.
LV11940A (lv) Melatonina pielietojums personu arstesanai kuras cies no zalu atkaribas
FR2710539B1 (fr) Ensemble d'aiguille chirurgicale.
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69609541D1 (de) Verwendung von 6,7-substituierten-2-Aminotetraline zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von septischem Schock, und antipyretischer und antientzündlicher Zusammensetzungen
NO984964L (no) Anvendelse av fosfonsyreestere for behandling av funksjonelle forstyrrelser i hjernen og ved depresjon